Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Capitol Comprehensive Cancer Care Clinic and Research Institute
mi
from
Jefferson City, MO
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Capitol Comprehensive Cancer Care Clinic and Research Institute
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Nebraska Methodist Hospital
mi
from
Omaha, NE
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
The Ohio State University James Cancer Hospital
mi
from
Columbus, OH
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
The Ohio State University James Cancer Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
St Luke'S Hospital And Health Network
mi
from
Bethlehem, PA
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
St Luke'S Hospital And Health Network
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Hollings Cancer Center
mi
from
Charleston, SC
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Hollings Cancer Center
mi
from
Charleston, SC
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Vermont Cancer Center at Fletcher Allen Health Care
mi
from
Burlington, VT
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Vermont Cancer Center at Fletcher Allen Health Care
mi
from
Burlington, VT
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Peninsula Cancer Institute
mi
from
Newport News, VA
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Peninsula Cancer Institute
mi
from
Newport News, VA
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
mi
from
Klagenfurt,
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Klagenfurt,
Click here to add this to my saved trials
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Vitamin D, Insulin Resistance, and Cardiovascular Disease
Vitamin D, Insulin Resistance, and Cardiovascular Disease
Status: Enrolling
Updated:  12/31/1969
Washington Universiy
mi
from
Saint Louis, MO
Vitamin D, Insulin Resistance, and Cardiovascular Disease
Vitamin D, Insulin Resistance, and Cardiovascular Disease
Status: Enrolling
Updated: 12/31/1969
Washington Universiy
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism
Comparing Pump vs. Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism
Comparing Pump vs. Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Regression of Fatty Heart by Valsartan Therapy
Regression of Fatty Heart by Valsartan Therapy
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Regression of Fatty Heart by Valsartan Therapy
Regression of Fatty Heart by Valsartan Therapy
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Exercise and Inflammation in the Elderly
Exercise, Inflammation and Pro-thrombotic Modulators in the Elderly
Status: Enrolling
Updated:  12/31/1969
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
mi
from
Baltimore, MD
Exercise and Inflammation in the Elderly
Exercise, Inflammation and Pro-thrombotic Modulators in the Elderly
Status: Enrolling
Updated: 12/31/1969
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effect of Endoplasmic Reticulum Stress on Metabolic Function
Effect of Endoplasmic Reticulum Stress on Metabolic Function
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Effect of Endoplasmic Reticulum Stress on Metabolic Function
Effect of Endoplasmic Reticulum Stress on Metabolic Function
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass
A Randomized, Controlled Trial Comparing the Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass in Patients With Impaired Fasting Glucose or Early Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Rodebaugh Diabetes Center, Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass
A Randomized, Controlled Trial Comparing the Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass in Patients With Impaired Fasting Glucose or Early Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Rodebaugh Diabetes Center, Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass
A Randomized, Controlled Trial Comparing the Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass in Patients With Impaired Fasting Glucose or Early Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Clinical and Translational Research Center, Hospital of University of Pennsylvania
mi
from
Philadelphia, PA
Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass
A Randomized, Controlled Trial Comparing the Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass in Patients With Impaired Fasting Glucose or Early Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Clinical and Translational Research Center, Hospital of University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass
A Randomized, Controlled Trial Comparing the Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass in Patients With Impaired Fasting Glucose or Early Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Pennsylvania Hospital
mi
from
Philadelphia, PA
Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass
A Randomized, Controlled Trial Comparing the Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass in Patients With Impaired Fasting Glucose or Early Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Pennsylvania Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine
Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine
Status: Enrolling
Updated:  12/31/1969
Univerisity of Maryland, Baltimore
mi
from
Baltimore, MD
Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine
Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine
Status: Enrolling
Updated: 12/31/1969
Univerisity of Maryland, Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
Reversal of Hypoglycemia Unawareness Using Continuous Glucose Monitoring
Reversal of Hypoglycemia Unawareness Using Continuous Glucose Monitoring
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Reversal of Hypoglycemia Unawareness Using Continuous Glucose Monitoring
Reversal of Hypoglycemia Unawareness Using Continuous Glucose Monitoring
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
La Jolla, CA
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Orange, CA
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cleveland, OH
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Hershey, PA
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hershey, PA
Click here to add this to my saved trials
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Salt Lake City, UT
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Milwaukee, WI
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated:  12/31/1969
mi
from
Edmonton,
Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU
A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria
Status: Enrolling
Updated: 12/31/1969
mi
from
Edmonton,
Click here to add this to my saved trials
Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
University of North Carolina Medical Center
mi
from
Chapel Hill, NC
Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
University of North Carolina Medical Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Medical Univerrsity of South Carolina
mi
from
Charleston, SC
Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Medical Univerrsity of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients
Effects of Dietary and Behavioral Intervention and Orlistat for Management of Obesity and Metabolic Syndrome on Response to Hepatitis C Therapy
Status: Enrolling
Updated:  12/31/1969
Center for Liver Diseases, UPMC.
mi
from
Pittsburgh, PA
Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients
Effects of Dietary and Behavioral Intervention and Orlistat for Management of Obesity and Metabolic Syndrome on Response to Hepatitis C Therapy
Status: Enrolling
Updated: 12/31/1969
Center for Liver Diseases, UPMC.
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Trial of Aerobic Exercise Training in Stroke Survivors
Aging, Inflammation and Exercise in Chronic Stroke
Status: Enrolling
Updated:  12/31/1969
University of Maryland, VAMC
mi
from
Baltimore, MD
Trial of Aerobic Exercise Training in Stroke Survivors
Aging, Inflammation and Exercise in Chronic Stroke
Status: Enrolling
Updated: 12/31/1969
University of Maryland, VAMC
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Little Rock, AR
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Facility #1
mi
from
La Jolla, CA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Facility #1
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Los Gatos, CA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Los Gatos, CA
Click here to add this to my saved trials
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Mission Viejo, CA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Orange, CA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Orange, CA
Click here to add this to my saved trials
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Facility 2
mi
from
Orange, CA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Facility 2
mi
from
Orange, CA
Click here to add this to my saved trials
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Sacramento, CA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Torrance, CA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Torrance, CA
Click here to add this to my saved trials
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Facility # 1
mi
from
Aurora, CO
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Facility # 1
mi
from
Aurora, CO
Click here to add this to my saved trials